A federal judge in Newark, N.J., on Thursday dismissed a class action claiming that Schering-Plough Corp. violated antitrust law by paying generic drug makers to delay introduction of knockoffs of its potassium-deficiency drug K-Dur.

Judge Joseph Greenaway Jr. adopted the report of special master Stephen Orlofsky, who found no merit in the plaintiffs’ argument that license fees Schering paid as part of a settlement of patent litigation against the competitors were presumptively anticompetitive.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]